Centre Hospitalier Universitaire de Limoges

Running trials

• Not yet recruiting

  Prognostic and Predictive Factors in Childhood Soft Tissue Sarcomas

  NCT07924384· Institut Curie· Source

• Recruiting

  Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse

  NCT07871864· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source

• Not yet recruiting

  Follow-up After Oncological Resection by Endoscopic Colorectal ESD (Endoscopic Submucosal Dissection)

  NCT07871227· University Hospital, Bordeaux· Source

• Not yet recruiting

  Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.

  NCT07463768· Phase 2· French Innovative Leukemia Organisation· Source

• Recruiting

  International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)

  NCT07476729· Phase 3· Charite University, Berlin, Germany· Source

• Not yet recruiting

  Physical Activity Level at Home in CMT1A Patients: Wearable Sensor Assessment

  NCT07591779· University Hospital, Limoges· Source

• Recruiting

  Determinants and Consequences of the Transition to Adulthood for Adolescents With Severe Haemophilia: TRANSHEMO 2, an Ancillary Study to the TRANSHEMO Project

  NCT07418827· Assistance Publique Hopitaux De Marseille· Source

• Recruiting

  Cohort of Patients With Chronic Myelomonocytic Leukemia

  NCT07512882· Gustave Roussy, Cancer Campus, Grand Paris· Source

• Recruiting

  Efficacy of CAD in Screening Colonoscopy to Reduce the Risk of Advanced Adenoma at 3 Years.

  NCT07299071· University Hospital, Bordeaux· Source

• Recruiting

  Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)

  NCT06937905· Phase 3· Intergroupe Francophone de Cancerologie Thoracique· Source

• Recruiting

  Stratification of Arrhythmic Risk and/or Heart Failure Risk in Patients With Hereditary Heart Disease

  NCT07257289· Nantes University Hospital· Source

• Not yet recruiting

  FILO-AML-01-MIVONU A single arm phase II study investigating the efficacy and safety of the addition of ivosidenib to oral azacitidine (Onureg®) in patients over 55 with Acute Myeloid Leukemia (AML) and IDH1 mutation, in complete remission after intensive chemotherapy. A study of the French AML Intergroup.

  2025-521322-14-00· Phase 2· French Innovative Leukemia Organization· Source

• Recruiting

  Is Non Surgical CaRE Using Treat to Target Multimodal meDIcal Strategies aBLE to Delay or Avoid Total Knee Replacement?

  NCT06643845· University Hospital, Brest· Source

• Recruiting

  Integrating AI in Stroke Neurorehabilitation

  NCT07138495· Eodyne Systems SL· Source

• Recruiting

  Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma

  NCT07205731· Phase 2· University Hospital, Clermont-Ferrand· Source

• Not yet recruiting

  Interest of Preoperative Arteriography to Identify the Adamkiewicz Artery Before Surgery for Basi-thoracic Neuroblastic Tumors

  NCT06798532· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa

  NCT07136467· AbbVie· Source

• Recruiting

  Identification and Characterisation of IgA With Nephritogenic Potential in IgA Deposition Nephropathies (Rep-IgAN)

  NCT07295808· University Hospital, Limoges· Source

• Not yet recruiting

  Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)

  NCT06931704· Phase 2· Nantes University Hospital· Source

• Recruiting

  Evaluation of Software for Interpreting Virological Results Indicated for the Diagnosis of Cytomegalovirus (CMV) Infection During Pregnancy and Intended for Health Professionals

  NCT06694428· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Multimodal Biocollection Linked to the French Register of Intracranial Aneurysms

  NCT06689410· Nantes University Hospital· Source

• Recruiting

  PMCF Registry to Describe the Safety and Performance of p64, p48 MW and p64 MW in France

  NCT07748572· Phenox GmbH· Source

• Recruiting

  Long-term Evaluation of the SIMEOX Device at Home in Non-cystic Fibrosis Bronchiectasis

  NCT06487273· Physio-Assist· Source

• Recruiting

  An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis

  NCT06764693· AbbVie· Source

• Recruiting

  Indication of HSCT in Patients With Refractory/Relapse AA After First-line Standard Immunosuppressive Therapy Aged More Than 40 Years

  NCT06646497· Phase 2· Assistance Publique - Hôpitaux de Paris· Source

• Recruiting

  Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context

  NCT06487078· Pfizer· Source

• Recruiting

  Detection of Homologous Recombination Pathway Gene Mutations in Circulating Tumour DNA From BRCA-mutated Ovarian Cancer Patients Receiving First-line PARP Inhibitor Maintenance Therapy

  NCT06588322· Institut Claudius Regaud· Source

• Active, not recruiting

  Study To Assess Effectiveness and Adverse Events of Foscarbidopa/ Foslevodopa in Adult Participants With Advanced Parkinson Disease in Real Life Setting

  NCT06639620· AbbVie· Source

• Recruiting

  EkiYou-Study-2 : A National Multicentric Trial of the EkiYou Application for Insulin Bolus Calculation

  NCT06738849· DiappyMed· Source

• Recruiting

  Epidemiological Data on Mast Cell Pathologies in France

  NCT06186856· Imagine Institute· Source

• Recruiting

  Developmental and Epileptic Encephalopathy of Genetic Etiology: Natural History Through Reuse of Clinical Data

  NCT06380192· Imagine Institute· Source

• Active, not recruiting

  Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas

  NCT06557889· Phase 2· Institut Claudius Regaud· Source

• Recruiting

  LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

  NCT06216301· Phase 3· NovoCure GmbH· Source

• Recruiting

  Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis

  NCT05841758· Phase 4· Hospices Civils de Lyon· Source

• Recruiting

  Cardiac Amyloidosis pRevaleNce of in OLDer Subjects Affected by Heart Failure

  NCT06427304· Gérond'if· Source

• Recruiting

  Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer

  NCT06712472· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source

• Active, not recruiting

  Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma

  NCT06353022· Phase 2· Nantes University Hospital· Source

• Recruiting

  Trial Evaluating the Rate of Pneumothorax in Severe Emphysema Secondary to Endoscopic Volume Reduction With Two-stage ZEPHYR® Valves Versus Endoscopic Volume Reduction With One-stage ZEPHYR® Valves

  NCT06181357· University Hospital, Limoges· Source

• Recruiting

  Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

  NCT05485961· Phase 2/3· CSL Behring· Source

• Recruiting

  FILOCLL015 - GLORIFY - A phase 2 study evaluating the bispecific CD3xCD20 antibody GLOfitamab in combination with rituximab or obinutuzumab plus cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) in patients with RIchter syndrome as Frontline therapY

  2022-501554-11-00· Phase 2· French Innovative Leukemia Organization· Source

• Recruiting

  An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema

  NCT06035120· Pulmonx Corporation· Source

• Recruiting

  An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations

  2023-503865-48-00· Phase 2· Taiho Oncology Inc.· Source

• Recruiting

  Remotely Supervised Computerized Cognitive Stimulation to Reduce Post-chemotherapy Cognitive Difficulties in Patients Treated for Localized Breast Cancer

  NCT06027632· Centre Francois Baclesse· Source

• Recruiting

  A Phase 1/2 study of Enzomenib (DSP-5336) in Patients with Acute leukemia

  2022-502741-10-00· Phase 1/2· Sumitomo Pharma America Inc.· Source

• Recruiting

  DELTA DESCRIBE: the French Collaborative Project

  NCT05936073· University Hospital, Limoges· Source

• Recruiting

  Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia

  NCT06022003· Phase 2· French Innovative Leukemia Organisation· Source

• Recruiting

  PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer

  NCT05581121· Phase 3· Institut Claudius Regaud· Source

• Active, not recruiting

  REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

  NCT05973773· Phase 3· Taiho Oncology, Inc.· Source

• Recruiting

  A Study to Evaluate Pre-operative HYPOfractionated Radiation Therapy in Aged (≥ 70 Years Old) or "Fragile" (≥ 65 Years) Patients With Limb or Trunk Soft Tissue SARComa.

  NCT06022159· Phase 2· Institut Claudius Regaud· Source

• Recruiting

  Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA Matched Unrelated Donor

  NCT06083129· Phase 3· Assistance Publique - Hôpitaux de Paris· Source

Showing 50 of 108.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers11 recruiting
• Acute myeloid leukaemia8 recruiting
• Lung cancer6 recruiting
• Stroke6 recruiting
• Sarcoma4 recruiting
• Colorectal cancer3 recruiting
• HIV3 recruiting
• Multiple myeloma3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Aplastic anaemia2 recruiting
• Brain aneurysm2 recruiting
• Chronic kidney disease2 recruiting
• Chronic myeloid leukaemia2 recruiting
• COPD2 recruiting
• Cytomegalovirus infection2 recruiting
• Epilepsy2 recruiting
• Heart failure2 recruiting
• Hepatitis C2 recruiting
• Myelodysplastic syndromes2 recruiting
• Alopecia areata1 recruiting
• Amyloidosis1 recruiting
• Autism1 recruiting
• Bronchiectasis1 recruiting
• Cervical cancer1 recruiting
• Charcot-Marie-Tooth disease1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Coronary artery disease1 recruiting
• Cystic fibrosis1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Endometrial cancer1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Haemophilia1 recruiting
• Hepatitis B1 recruiting
• Hidradenitis suppurativa1 recruiting
• High blood pressure1 recruiting
• IgA nephropathy1 recruiting
• Kidney cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Neuroblastoma1 recruiting
• Neuroendocrine tumours1 recruiting
• Osteoarthritis1 recruiting
• Ovarian cancer1 recruiting
• Parkinson disease1 recruiting
• Peripheral artery disease1 recruiting
• Psoriasis1 recruiting
• Psoriatic arthritis1 recruiting
• Sarcoidosis1 recruiting
• Type 1 diabetes1 recruiting
• Type 2 diabetes1 recruiting
• Vitiligo1 recruiting

Closed trials

• Completed

  How Stroke Affects Leg Muscles When Walking

  NCT07504627· University Hospital, Limoges· Source

• Withdrawn

  Towards Optimal Screening and Management of Coronary Artery Disease in Diabetes: TOSCANA Study

  NCT05314140· French Cardiology Society· Source

• Completed

  Personality and Quality of Life Amelioration After Continuous Subcutaneous Apomorphine Infusion in Parkinson's Disease

  NCT06080399· University Hospital, Toulouse· Source

• Completed

  TRansmural hEaliNg Definition in CroHn's Disease (TRENCH 1)

  NCT05903066· Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives· Source

• Active, not recruiting

  A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

  NCT05904886· Phase 3· Hoffmann-La Roche· Source

• Completed

  Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

  NCT05882734· Phase 1/2· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  PRODIGE 81-FFCD 2101-TRIPLET: Study evaluating the benefit of adding Ipilimumab to the combination of Atezolizumab and Bevacizumab in patients with hepatocellular carcinoma receiving first-line systemic therapy-

  2022-501217-31-00· Phase 2/3· Fondation Franc.Cancerologie Digestive· Source

• Completed

  An Observational Study to Assess Change in Disease Activity and Treatment Patterns of Upadacitinib When Given Alone or Co-Administered With Methotrexate in Adult Participants With Active Psoriatic Arthritis

  NCT05616871· AbbVie· Source

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Bayer AG· Source

• Completed

  Comparison of the ENDOCUFF VISION® Endoscopy Cap Coupled With GI GENIUS™ Artificial Intelligence Compared to Each Device Alone in Improving Colonic Adenoma Detection Rate During Colonoscopy

  NCT05594576· Centre Hospitalier Universitaire de Nīmes· Source

• Completed

  A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)

  NCT05508867· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Specific Immune Reconstitution After Allogeneic Transplantation and Letermovir Prophylaxis

  NCT07915505· University Hospital, Limoges· Source

• Completed

  Computed Tomography-Guided Catheter Ablation for Ventricular Tachycardia

  NCT05225935· University Hospital, Bordeaux· Source

• Completed

  Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus

  NCT05232071· Phase 2· Inventiva Pharma· Source

• Completed

  Safety of Exposure to Natalizumab During Pregnancy

  NCT05209815· University Hospital, Bordeaux· Source

• Active, not recruiting

  Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)

  NCT05224141· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)

  NCT05248646· Phase 3· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source

• Completed

  A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis

  NCT04973137· Phase 3· Prothena Biosciences Limited· Source

• Completed

  Multicenter Retrospective Observatory of Patients With Acute Myeloid Leukemia to Core Binding Factor

  NCT05070208· Acute Leukemia French Association· Source

• Completed

  Clotild® Smart Guidewire System (CSGS) Evaluation in EndovascUlar Thrombectomy Procedure

  NCT04993079· Sensome· Source

• Completed

  Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

  NCT04971785· Phase 2· Gilead Sciences· Source

• Terminated

  Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated

  NCT04778397· Phase 3· Gilead Sciences· Source

• Completed

  Molecular Profiling of Exosomes in Tumor-draining Vein of Early-staged Lung Cancer

  NCT04939324· University Hospital, Limoges· Source

• Terminated

  An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas

  NCT05011058· Phase 2· Viracta Therapeutics, Inc.· Source

• Terminated

  To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

  NCT04551053· Phase 3· Incyte Corporation· Source

• Completed

  Multicentric Prospective Study to Screen Inborn Errors of Metabolism in Non-immune Hydrops (NIH) Fetalis by Massively Parallel Sequencing

  NCT04308603· Hospices Civils de Lyon· Source

• Completed

  Fissure Closure With the AeriSeal System for CONVERTing Collateral Ventilation Status (CONVERT)

  NCT04559464· Pulmonx Corporation· Source

• Completed

  Randomized Placebo Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.

  NCT03947216· Phase 2· University Hospital, Strasbourg, France· Source

• Completed

  A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid Arthritis

  NCT04497597· AbbVie· Source

• Completed

  AntiCMV molécules Monitoring in Real-life in Stem Cell Recipients

  NCT04690933· University Hospital, Limoges· Source

• Terminated

  Assessment of Quitting Versus Using Aspirin Therapy In Patients Treated With Oral Anticoagulation for Atrial Fibrillation or Other Indication With Stabilized Coronary Artery Disease

  NCT04217447· Phase 3· University Hospital, Brest· Source

• Terminated

  Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia

  NCT03765541· Phase 3· University Hospital, Toulouse· Source

• Completed

  Concordance and Accuracy of MRI in the Detection of Meningiomas: Optimizing Sequences With Low Doses of Gadolinium

  NCT04113395· Fondation Ophtalmologique Adolphe de Rothschild· Source

• Completed

  Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (allo-SCT) in FLT3-ITD AML Patients

  NCT03690115· Phase 2· Versailles Hospital· Source

• Completed

  Cognition Evolution and MRI Markers in PPMS Patients on 2 Years

  NCT03455582· University Hospital, Bordeaux· Source

• Completed

  Register of Patients With haEmophilia A tReated With Afstyla®

  NCT04675541· CSL Behring· Source

• Completed

  Transvenous Approach for the Treatment of Cerebral Arteriovenous Malformations

  NCT03691870· Centre hospitalier de l'Université de Montréal (CHUM)· Source

• Completed

  A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan in Clinical Studies.

  NCT03422328· Phase 3· Actelion· Source

• Completed

  Study Venetoclax Effectiveness and Real-Life Treatment Management in Participants With Chronic Lymphocytic Leukemia

  NCT03415035· AbbVie· Source

• Completed

  Evaluation of the Impact of Multiple Sclerosis and Its Treatments on Women Fertility

  NCT07164924· University Hospital, Clermont-Ferrand· Source

• Completed

  Study of Inotuzumab Ozogamicin Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor ALL

  NCT03249870· Phase 2· Versailles Hospital· Source

• Completed

  A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

  NCT03301220· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance

  NCT02896582· Phase 2· The Lymphoma Academic Research Organisation· Source

• Completed

  Interest of Continuous Non-Steroidal Anti-Inflammatory Drug Treatment in Ankylosing Spondylitis Patients Treated by Anti-TNF Therapy in the Prevention of Radiographic Outcomes

  NCT02469753· Phase 3· University Hospital, Bordeaux· Source

• Completed

  Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)

  NCT01868269· Phase 3· Institut Curie· Source

• Completed

  Radical Versus Simple Hysterectomy and Pelvic Node Dissection With Low-risk Early Stage Cervical Cancer

  NCT01658930· Canadian Cancer Trials Group· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Aplastic anaemia3 works · 2 trials